Table 2. Cost-effectiveness ceiling on effective vaccine cost if all EV71-HFMD cases were registered by the national HFMD surveillance.
| Scenario | Societal Perspective | Excluding Productivity Loss of Parents/Caregivers | ||||||
|---|---|---|---|---|---|---|---|---|
| 3% Discounting | 6% Discounting | 3% Discounting | 6% Discounting | |||||
| WTP 1 × GDPpc | WTP 3 × GDPpc | WTP 1 × GDPpc | WTP 3 × GDPpc | WTP 1 × GDPpc | WTP 3 × GDPpc | WTP 1 × GDPpc | WTP 3 × GDPpc | |
| A (base case) | 17.9 (16.9–18.8) | 32.4 (31.0–33.7) | 14.6 (13.7–15.4) | 23.5 (22.5–24.6) | 16.0 (15.2–16.8) | 30.5 (29.3–31.7) | 12.8 (12.1–13.5) | 21.7 (20.8–22.7) |
| B | 22.0 (20.6–23.3) | 37.2 (35.5–38.8) | 18.5 (17.2–19.7) | 28.1 (26.7–29.5) | 19.3 (18.2–20.4) | 34.5 (33.0–36.0) | 15.9 (14.9–16.9) | 25.5 (24.3–26.7) |
| C | 28.1 (26.2–29.9) | 44.4 (42.3–46.6) | 24.3 (22.5–26.0) | 34.9 (33.0–36.9) | 24.1 (22.6–25.6) | 40.5 (38.6–42.3) | 20.5 (19.1–21.9) | 31.2 (29.5–32.8) |
| D | 19.0 (18.1–20.0) | 34.7 (33.4–36.1) | 15.4 (14.6–16.3) | 25.1 (24.0–26.2) | 17.1 (16.3–17.9) | 32.8 (31.6–34.1) | 13.7 (12.9–14.4) | 23.3 (22.3–24.3) |
| E | 23.1 (21.8–24.4) | 39.5 (37.9–41.2) | 19.3 (18.1–20.6) | 29.7 (28.2–31.1) | 20.4 (19.3–21.5) | 36.8 (35.3–38.3) | 16.7 (15.7–17.8) | 27.1 (25.8–28.3) |
| F | 29.2 (27.4–31.1) | 46.8 (44.6–49.0) | 25.1 (23.4–26.9) | 36.5 (34.6–38.5) | 25.2 (23.7–26.8) | 42.8 (40.9–44.7) | 21.4 (19.9–22.8) | 32.7 (31.1–34.4) |
| G | 19.3 (18.4–20.3) | 35.4 (34.1–36.8) | 15.7 (14.8–16.6) | 25.6 (24.5–26.6) | 17.5 (16.6–18.3) | 33.5 (32.3–34.8) | 13.9 (13.2–14.7) | 23.8 (22.8–24.7) |
| H | 23.4 (22.1–24.8) | 40.2 (38.6–41.9) | 19.6 (18.4–20.8) | 30.1 (28.7–31.5) | 20.7 (19.6–21.8) | 37.5 (36.0–39.0) | 17.0 (16.0–18.0) | 27.5 (26.3–28.8) |
| I | 29.6 (27.7–31.4) | 47.5 (45.3–49.7) | 25.4 (23.7–27.1) | 37.0 (35.1–38.9) | 25.6 (24.0–27.1) | 43.5 (41.6–45.4) | 21.6 (20.2–23.0) | 33.2 (31.5–34.8) |
| J | 18.1 (17.0–19.1) | 32.3 (30.9–33.6) | 14.8 (13.9–15.8) | 23.6 (22.5–24.7) | 16.1 (15.2–17.0) | 30.3 (29.0–31.6) | 13.0 (12.2–13.8) | 21.8 (20.8–22.8) |
| K | 21.5 (20.2–22.8) | 36.3 (34.7–38.0) | 18.1 (16.9–19.3) | 27.5 (26.1–28.9) | 18.8 (17.7–19.9) | 33.6 (32.2–35.1) | 15.5 (14.5–16.5) | 24.9 (23.7–26.1) |
| L | 26.9 (25.1–28.7) | 42.7 (40.6–44.8) | 23.2 (21.5–24.8) | 33.5 (31.7–35.4) | 23.0 (21.6–24.5) | 38.9 (37.1–40.7) | 19.6 (18.2–20.9) | 29.9 (28.3–31.5) |
| M | 19.7 (18.6–20.7) | 35.5 (34.0–36.9) | 16.1 (15.1–17.0) | 25.8 (24.7–26.9) | 17.7 (16.8–18.6) | 33.5 (32.2–34.8) | 14.2 (13.4–15.0) | 23.9 (22.9–25.0) |
| N | 28.5 (26.7–30.2) | 45.9 (43.8–48.0) | 24.4 (22.8–26.1) | 35.7 (33.8–37.6) | 24.6 (23.2–26.0) | 42.1 (40.2–43.9) | 20.8 (19.4–22.1) | 32.1 (30.5–33.6) |
| O | 20.1 (19.1–21.2) | 36.4 (34.9–37.8) | 16.4 (15.5–17.4) | 26.4 (25.3–27.6) | 18.1 (17.2–19.0) | 34.4 (33.0–35.7) | 14.5 (13.7–15.4) | 24.5 (23.5–25.6) |
| P | 23.6 (22.2–24.9) | 40.4 (38.8–42.1) | 19.7 (18.4–20.9) | 30.3 (28.8–31.7) | 20.8 (19.7–21.9) | 37.7 (36.2–39.2) | 17.1 (16.0–18.1) | 27.7 (26.4–28.9) |
| Q | 28.9 (27.2–30.7) | 46.8 (44.7–49.0) | 24.8 (23.1–26.4) | 36.3 (34.5–38.2) | 25.1 (23.6–26.5) | 42.9 (41.1–44.8) | 21.1 (19.8–22.4) | 32.6 (31.1–34.2) |
| R | 18.6 (17.7–19.5) | 34.2 (32.9–35.5) | 15.0 (14.2–15.8) | 24.6 (23.6–25.6) | 16.7 (16.0–17.5) | 32.4 (31.2–33.6) | 13.3 (12.6–14.0) | 22.9 (21.9–23.8) |
| S | 29.7 (27.8–31.6) | 47.4 (45.1–49.6) | 25.6 (23.8–27.4) | 37.1 (35.1–39.1) | 25.6 (24.1–27.2) | 43.3 (41.3–45.2) | 21.7 (20.3–23.2) | 33.2 (31.5–34.9) |
The mean and 95% CI of EVCmax are listed for each scenario.
WTP, willingness-to-pay threshold.